MILESTONE PHARMS USA
PharmaMILESTONE PHARMS USA is a pharmaceutical company with 1 FDA-approved products.
MILESTONE PHARMS USA at a Glance
- Fast trial execution (33 months median completion)
MILESTONE PHARMS USA's Key Drugs
MILESTONE PHARMS USA's core commercial portfolio centers on CARDAMYST — its most strategically important drugs approved in the last 15 years.
MILESTONE PHARMS USA News
All MILESTONE PHARMS USA news →- Nov 13, 2026 EarningsMilestone Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through AFib-RVR Phase 3 Data ↗
- Nov 2, 2026 TrialsNew Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation ↗
- Oct 19, 2026 TrialsMilestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences ↗
- Oct 9, 2026 TrialsMilestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial ↗
- Sep 24, 2026 TrialsMilestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR ↗
MILESTONE PHARMS USA's Recent FDA Approvals
MILESTONE PHARMS USA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
MILESTONE PHARMS USA's Therapeutic Areas
Disease areas where MILESTONE PHARMS USA has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MILESTONE PHARMS USA Pipeline Snapshot
Active clinical trials for MILESTONE PHARMS USA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CARDAMYST leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 1/5 completed
- • Speed: 33 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-12-12
- Latest
- 2025-12-12
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges